Hematopoietic Cell Transplantation for Autoimmune Diseases
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 9.053 alerts
Get alerted when Policy MP 9.053 changes without checking for updates manually.
Monitor payer policy activity
Defines Capital Bluecross policy stance on use of hematopoietic cell transplantation (HCT) to treat various autoimmune diseases and lists coding and evidence references; affects providers requesting coverage for HCT for autoimmune indications.
No material clinical or coverage changes in this revision.
Coverage Criteria — Hematopoietic Cell Transplantation for Autoimmune Diseases
Autoimmune arthritis (juvenile idiopathic or rheumatoid)
Policy statements and evidence summaries for specific autoimmune disease groups
Supports investigational/insufficient evidence conclusion.
CIDP
Insufficient evidence.
Type 1 diabetes
Insufficient evidence due to heterogeneity and study limitations.
Other autoimmune diseases
RCTs cited including ASTIC and related analyses.
Hematopoietic cell transplantation (HCT) for autoimmune diseases is designated investigational and therefore not covered. This investigational designation is explicitly stated in the Coding Information section and applies to HCT when used as a treatment for autoimmune disease indications.
There are no additional explicit coverage exclusions listed elsewhere in the referenced policy chunks. The policy history and administrative notes document reviews and formatting updates but do not add specific exclusion statements beyond the investigational designation noted in the Coding Information section.
Within the provided sections, there are no explicit statements labeling any uses of HCT for autoimmune diseases as not medically necessary. The clinical evidence summaries reference insufficient evidence for multiple autoimmune indications, but the document does not present discrete 'not medically necessary' conditions in the cited chunks.
Coding — Procedure and Diagnosis Codes
| No codes listed |
| M34.0 | Progressive systemic sclerosis |
| M34.1 | CR(E)ST syndrome |
| M34.2 | Systemic sclerosis induced by drug and chemical |
| M34.81 | Systemic sclerosis with lung involvement |
| M34.82 | Systemic sclerosis with myopathy |
| M34.83 | Systemic sclerosis with polyneuropathy |
| M34.89 | Other systemic sclerosis |
| M34.9 | Systemic sclerosis, unspecified |
Provider Actions and Billing Notes
Procedure codes listed as covered vs investigational stance
Procedure codes 38232, 38207, 38241, 38208, S2150, 38211, 38212, 38213, 38214, and 38215 are listed in the policy under “Covered when medically necessary,” while elsewhere HCT for autoimmune diseases is described as investigational and not covered; coverage determinations depend on member benefits and medical necessity and prior authorization may be required.
No specific prior authorization requirements documented
The policy text does not list any specific prior authorization forms, processes, or affected billing codes beyond the coding lists; no explicit prior authorization requirements are specified in the cited chunks.
- No prior authorization form or explicit PA process described in these sections
- Coding lists are provided but do not by themselves establish PA requirements
Coding and coverage note — code identification does not guarantee coverage
Coding information notes that the code lists may not be all‑inclusive and that identification of a code in the policy does not denote coverage; coverage is determined by member benefit terms and medical necessity.
- “Note: This list of codes may not be all‑inclusive, and codes are subject to change at any time.”
- “The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information.”
No step therapy requirements stated
No step therapy requirements or stepwise treatment prerequisites are described in the cited policy sections.
Coding lists may be incomplete; code presence ≠ coverage
The policy cautions that the listed procedure and diagnosis code lists may not be all‑inclusive and that code identification does not indicate coverage; final coding and coverage determination will be made during claims processing according to member benefit terms.
- Code lists are subject to change and may be incomplete
- Identification of a code in the policy does not denote coverage
Policy history present; no specific documentation checklist provided
Policy history and administrative updates are recorded in the document, but the cited sections do not specify required documentation elements or a prior authorization form.
- Multiple policy history entries are listed (2019–2026) with coding and references reviewed
- No explicit documentation checklist or PA form is provided in these chunks
Investigational indication — submission risks denial
Hematopoietic cell transplantation (HCT) for autoimmune diseases is labeled investigational and therefore not covered; submitting requests for HCT for autoimmune indications may result in denial of coverage.
- Policy statement: “Investigational; therefore not covered, as a treatment of autoimmune diseases”
- Providers should expect denial risk when submitting claims for these indications
No explicit procedural authorization triggers described
The cited sections do not state explicit procedural authorization triggers or enumerate specific actions that will automatically result in denial beyond the investigational designation.
Background — Clinical Context and Evidence Summary
Hematopoietic cell transplantation (HCT) has been investigated across multiple autoimmune diseases including multiple sclerosis, systemic sclerosis, Crohn disease, type 1 diabetes, systemic lupus erythematosus, juvenile idiopathic arthritis, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The policy cites a range of evidence types — randomized trials (for example, trials in Crohn disease), registry analyses, observational studies, case series, and meta-analyses — assessing outcomes such as survival, symptom control, quality of life, treatment‑related mortality, and morbidity. Across these indications the policy summarizes that available data are heterogeneous and, for most autoimmune conditions reviewed, are insufficient to determine improvement in net health outcome.
Definitions
Pre-Transplant Evaluation Requirements
No pre‑transplant evaluation steps specified
The cited policy sections do not specify any required pre‑transplant evaluation steps or clinical workup that providers must follow prior to requesting HCT for autoimmune diseases.
Center and Program Requirements
No center accreditation or volume requirements specified
No center accreditation, minimum volume, or transplant‑center specific requirements are stated in the cited sections of the policy.
Post-Transplant Coverage and Related Policy
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.